Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenues (Tables)

Revenues (Tables)

9 Months Ended

Sep. 30, 2019

Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Product sales:
Gross product sales	$	14,348	$	6,132	$	36,745	$	8,419
Discounts and allowances		(2,632)		(1,267)		(6,802)		(1,767)
Product sales, net	$	11,716	$	4,865	$	29,943	$	6,652

Revenues from collaborations:
License revenues		7,750		—		12,249		—
Research and development services and others		1,391		—		1,696		—
Total revenues from collaborations		9,141		—		13,945		—
Total revenues	$	20,857	$	4,865	$	43,888	$	6,652

Schedule of revenues from product sales disaggregated by customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
ASD Healthcare and Oncology Supply		28%		58%		34%		53%
McKesson Specialty Care Distribution Corporation		22%		33%		27%		38%
Aclaris		19%		—		9%		—
Celgene		18%		—		9%		—
Grifols		0%		—		11%		—

Schedule of product revenue allowances and discounts

The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2019 (in thousands):


	Chargebacks,		Government
	Discounts and		and Other
	Fees		Rebates		Returns		Total
Balance at January 1, 2019	$	622	$	843	$	170	$	1,635
Provision related to current period sales		3,561		2,296		99		5,956
Credit or payments made during the period		(2,932)		(1,298)		—		(4,230)
Balance at September 30, 2019	$	1,251	$	1,841	$	269	$	3,361